000 04304cam a2200949 a 4500
001 ocn811850420
003 OCoLC
005 20171224114056.0
006 m o d
007 cr |||||||||||
008 121002s2013 nju ob 001 0 eng
010 _a 2012040270
040 _aDLC
_beng
_epn
_cDLC
_dYDX
_dDG1
_dN$T
_dYDXCP
_dE7B
_dCDX
_dIDEBK
_dCOO
_dNOC
_dOCLCF
_dCCO
_dNLGGC
_dRECBK
_dEBLCP
_dOCLCQ
_dOCLCO
_dD6H
_dLOA
019 _a828793860
_a961568624
_a962707379
_a966257693
020 _a9781118354582
_q(epub)
020 _a1118354583
_q(epub)
020 _a9781118354575
_q(pdf)
020 _a1118354575
_q(pdf)
020 _a9781118354568
_q(mobi)
020 _a1118354567
_q(mobi)
020 _a9781118354599
_q(electronic bk.)
020 _a1118354591
_q(electronic bk.)
020 _a9781299241954
_q(MyiLibrary)
020 _a1299241956
_q(MyiLibrary)
020 _z9780470646274
_q(cloth)
020 _z0470646276
_q(cloth)
029 1 _aAU@
_b000050086446
029 1 _aCHBIS
_b009914530
029 1 _aCHVBK
_b175204659
029 1 _aDKDLA
_b820120-katalog:000655910
029 1 _aNLGGC
_b356864928
029 1 _aNZ1
_b15340367
029 1 _aNZ1
_b15905471
029 1 _aDEBBG
_bBV043395079
035 _a(OCoLC)811850420
_z(OCoLC)828793860
_z(OCoLC)961568624
_z(OCoLC)962707379
_z(OCoLC)966257693
042 _apcc
050 0 0 _aRM301.4
_b.F87 2013
060 1 0 _aQU 450
072 7 _aMED
_x071000
_2bisacsh
082 0 0 _a615.7
_223
049 _aMAIN
245 0 0 _aFusion protein technologies for biopharmaceuticals :
_bapplications and challenges /
_cedited by Stefan R. Schmidt.
260 _aHoboken, New Jersey :
_bJohn Wiley & Sons,
_c©2013.
300 _a1 online resource.
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
504 _aIncludes bibliographical references and index.
588 0 _aPrint version record and CIP data provided by publisher.
505 0 _apt. 1. Introduction -- pt. 2. The triple t paradigm : time, toxin, targeting -- pt. 3. Beyond the triple t-paradigm.
520 _aThe state of the art in biopharmaceutical FUSION PROTEIN DESIGN Fusion proteins belong to the most lucrative biotech drugs-with Enbrel® being one of the best-selling biologics worldwide. Enbrel® represents a milestone of modern therapies just as Humulin®, the first therapeutic recombinant protein for human use, approved by the FDA in 1982 and Orthoclone® the first monoclonal antibody reaching the market in 1986. These first generation molecules were soon followed by a plethora of recombinant copies of natural human proteins, and in 1998, the first de novo designed fusion protei.
650 0 _aBiopharmaceutics.
650 0 _aPharmaceutical biotechnology.
650 4 _aDrug carriers.
650 4 _aImmunotoxins
_xTherapeutic use.
650 4 _aProtein engineering.
650 4 _aRecombinant fusion proteins
_xTherapeutic use.
650 7 _aMEDICAL
_xPharmacology.
_2bisacsh
650 7 _aBiopharmaceutics.
_2fast
_0(OCoLC)fst00832650
650 7 _aPharmaceutical biotechnology.
_2fast
_0(OCoLC)fst01060106
650 2 _aRecombinant Fusion Proteins
_xtherapeutic use.
650 2 _aDrug Carriers.
650 2 _aImmunotoxins
_xpharmacokinetics.
650 2 _aImmunotoxins
_xtherapeutic use.
650 2 _aProtein Engineering.
650 2 _aRecombinant Fusion Proteins
_xpharmacokinetics.
655 4 _aElectronic books.
655 7 _aElectronic books.
_2local
700 1 _aSchmidt, Stefan R.
776 0 8 _iPrint version:
_tFusion protein technologies for biopharmaceuticals.
_dHoboken, N.J. : John Wiley & Sons, ©2013
_z9780470646274
_w(DLC) 2012039440
856 4 0 _uhttp://onlinelibrary.wiley.com/book/10.1002/9781118354599
_zWiley Online Library
938 _aCoutts Information Services
_bCOUT
_n23452133
938 _aEBL - Ebook Library
_bEBLB
_nEBL1119446
938 _aebrary
_bEBRY
_nebr10662566
938 _aEBSCOhost
_bEBSC
_n542817
938 _aIngram Digital eBook Collection
_bIDEB
_ncis24878973
938 _aRecorded Books, LLC
_bRECE
_nrbeEB00063420
938 _aYBP Library Services
_bYANK
_n10247619
938 _aYBP Library Services
_bYANK
_n9571140
938 _aYBP Library Services
_bYANK
_n10253195
994 _a92
_bDG1
999 _c12210
_d12210